BioPharmSignal logoBioPharmSignal

Biotech News

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Humacyte (HUMA)HumacyteFDA / regulatory

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept.

Related news

HUMAHumacyte2026-03-17 12:00 EST

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

HUMAHumacyte2026-05-20 12:00 EST

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-09-10 12:00 EST

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUMAHumacyte2026-09-09 12:00 EST

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-08-19 12:00 EST

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

Stock data

Close
0.59 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States